Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit declines year over year

Q1 FY2026 gross profit of $3.58M fell 90.1% year over year, behind the -44.8% change in trailing-twelve-month gross profit. Sequentially, it fell 91.4% from the prior quarter. Over 3 fiscal years it compounded at -20.3% a year.

Context

  • Gross profit amounted to 81.5% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -90.1% toward the trailing-twelve-month pace of -44.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.58M-91.4% QoQ
Last fiscal yearDec 2025
$138.63M-26.5% YoY
LTMMar 2026
$105.94M-44.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-90.1%——
1 year-26.5%——
3-year CAGR-20.3%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
138.63M USD
Year-over-year change
-26.5%
4-year CAGR
-6.9%

Gross Profit vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.8% is the 6th highest of 8, against a peer median of +15.0%.
  • Gross profit amounts to 75.0% of revenue for DNA, versus a peer median of 72.4%.
DNA Competitors
Gross Profit for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$201.75M USD+169.7%—53.2%
VIRVir Biotechnology, Inc.LTM Mar 2026$180.27M USD+137.1%-61.5%275.2%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$105.94M USD-44.8%-20.3%75.0%
ARVNArvinas, Inc.LTM Mar 2026$87.1M USD-79.5%+25.1%97.4%
MGTXMeiraGTx Holdings plcLTM Mar 2026$73.09M USD+682.6%+68.8%91.6%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$72.25M USD+15.0%-64.0%34.6%
VALNValneva SELTM Mar 2026€46.05M EUR-46.8%+22.4%29.5%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$124K USD-24.0%——
REPLReplimune Group, Inc.LTM Dec 2025-$848K USD———
Peer median (excluding DNA) —+15.0%+22.4%72.4%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.